Symptoms_associated_with_tamoxifen_treatment_in_postmenopausal_women._Adjuvant_breast_cancer_therapy_with_tamoxifen_is_associated_with_greater_disease-free_survival_and_possibly_overall_survival._Long-term_treatment,_possibly_of_indefinite_duration,_is_being_evaluated._Compliance_with_long-term_therapy_will_depend_largely_on_the_nature_and_severity_of_tamoxifen's_side_effects._We_evaluated_the_symptoms_associated_with_tamoxifen_therapy_in_140_postmenopausal_women_with_axillary_node_negative_breast_cancer_in_remission_(mean_years_since_menopause,_9.3)_enrolled_in_a_placebo-controlled,_randomized_toxicity_study._Tamoxifen_recipients_reported_moderated_or_severe_vasomotor_symptoms_up_to_17%,_and_gynecologic_symptoms_up_to_4%_more_frequently_than_placebo_subjects._Persistent_vasomotor,_gynecologic,_or_other_major_side_effects_were_reported_by_48%_of_tamoxifen_recipients,_and_by_21%_of_placebo_subjects._These_carefully_collected_data_suggest_significant_perceived_symptom_'cost'_of_tamoxifen_therapy_in_postmenopausal_women,_of_a_magnitude_likely_to_compromise_long-term_compliance.